Literature DB >> 22398064

Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study.

Marte Lie Høivik1, Tomm Bernklev, Inger Camilla Solberg, Milada Cvancarova, Idar Lygren, Jørgen Jahnsen, Bjørn Moum.   

Abstract

BACKGROUND AND AIMS: Data on the long-term effects of Crohn's disease (CD) on health-related quality of life (HRQoL) is scarce. We aimed to determine the HRQoL in CD patients 10 years after disease onset, to compare the results to the general population and to identify variables that could affect HRQoL.
METHODS: CD patients from a population-based inception cohort (the IBSEN Study) met at a prescheduled ten-year follow-up. In addition to a structured interview, review of hospital records, clinical examination, laboratory tests and ileocolonoscopy, they completed a patient-reported questionnaire including the Short Form 36 (SF-36) and the Norwegian Inflammatory Bowel Disease Questionnaire (N-IBDQ). The SF-36 scores were compared to scores from the general population using one-sample t-tests. Standardized scores were calculated and interpreted according to Cohen's effect size index. The associations between relevant clinical and demographic factors and HRQoL were examined through linear regression analyses.
RESULTS: Ninety-nine patients completed the HRQoL questionnaires (response rate 86%). Median age 39 years, 42% women. Compared to the general population the patients reported significantly lower SF-36 scores on the general health and vitality dimensions. IBDQ total scores were in line with scores of patients in remission. Except for current symptom severity no clinical parameters affected HRQoL scores. Work status and sick leave affected HRQoL negatively.
CONCLUSIONS: In this chronic stage of CD, reduced general health and vitality scores need attention while reductions in disease specific HRQoL seem to be less predominant.
Copyright © 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22398064     DOI: 10.1016/j.crohns.2011.10.001

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  14 in total

1.  Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort.

Authors:  Lea K Christiansen; Bobby Lo; Flemming Bendtsen; Ida Vind; Marianne K Vester-Andersen; Johan Burisch
Journal:  United European Gastroenterol J       Date:  2019-05-17       Impact factor: 4.623

Review 2.  Impact of inflammatory bowel disease on disability.

Authors:  Katharina Büsch; Amnon Sonnenberg; Nick Bansback
Journal:  Curr Gastroenterol Rep       Date:  2014-10

Review 3.  Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients.

Authors:  Jørgen Jahnsen
Journal:  Therap Adv Gastroenterol       Date:  2016-03-21       Impact factor: 4.409

4.  Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis.

Authors:  Gert Huppertz-Hauss; Marte Lie Høivik; Ebbe Langholz; Selwyn Odes; Milada Småstuen; Reinhold Stockbrugger; Geir Hoff; Bjørn Moum; Tomm Bernklev
Journal:  Inflamm Bowel Dis       Date:  2015-02       Impact factor: 5.325

5.  Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease.

Authors:  Annika Gauss; Thomas Geiss; Ulf Hinz; Rainer Schaefert; Philipp Zwickel; Anna Zawierucha; Wolfgang Stremmel; Lukas Klute
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

6.  Comparison of the Multiattribute Utility Instruments EQ-5D and SF-6D in a Europe-Wide Population-Based Cohort of Patients with Inflammatory Bowel Disease 10 Years after Diagnosis.

Authors:  Gert Huppertz-Hauss; Eline Aas; Marte Lie Høivik; Ebbe Langholz; Selwyn Odes; Milada Småstuen; Reinhold Stockbrugger; Geir Hoff; Bjørn Moum; Tomm Bernklev
Journal:  Gastroenterol Res Pract       Date:  2016-08-18       Impact factor: 2.260

7.  Tolerance Limits, Self-understanding, and Stress Resilience in Integrative Recovery of Inflammatory Bowel Disease.

Authors:  Kari Skrautvol; Dagfinn Nåden
Journal:  Holist Nurs Pract       Date:  2017 Jan/Feb       Impact factor: 1.000

8.  The Use of Complementary and Alternative Medicine among Patients with Inflammatory Bowel Disease Is Associated with Reduced Health-Related Quality of Life.

Authors:  Randi Opheim; Marte Lie Høivik; Tomm Bernklev; Lars-Petter Jelsness-Jørgensen; Bjørn Moum
Journal:  Gastroenterol Res Pract       Date:  2016-11-27       Impact factor: 2.260

9.  Cerebral magnetic resonance imaging in quiescent Crohn's disease patients with fatigue.

Authors:  Sanne van Erp; Ece Ercan; Perla Breedveld; Lianne Brakenhoff; Eidrees Ghariq; Sophie Schmid; Matthias van Osch; Mark van Buchem; Bart Emmer; Jeroen van der Grond; Ron Wolterbeek; Daniel Hommes; Herma Fidder; Nic van der Wee; Tom Huizinga; Désirée van der Heijde; Huub Middelkoop; Itamar Ronen; Andrea van der Meulen-de Jong
Journal:  World J Gastroenterol       Date:  2017-02-14       Impact factor: 5.742

10.  Sense of coherence in patients with inflammatory bowel disease.

Authors:  Randi Opheim; May Solveig Fagermoen; Lars-Petter Jelsness-Jørgensen; Tomm Bernklev; Bjørn Moum
Journal:  Gastroenterol Res Pract       Date:  2014-01-02       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.